OS ANALYSIS OF 1L ABRAXANE + GEMCITABINE AND
SUBSEQUENT THERAPY9
OS ANALYSIS OF 1L ABRAXANE
+ GEMCITABINE AND SUBSEQUENT THERAPY9

A post-hoc analysisa of patients who went on to receive subsequent (2L) therapy9
A post hoc analysis of overall survival for patients who went on to receive subsequent therapy after ABRAXANE + gemcitabine A post hoc analysis of overall survival for patients who went on to receive subsequent therapy after ABRAXANE + gemcitabine
aAnalysis Limitations: A post-hoc exploratory analysis should not be interpreted to determine a treatment difference between arms at these selected time points, because of potential selection bias, insufficient sample size, and a higher probability of making a false positive error.
In patients who went on to receive 2L therapy:
  • Median duration of 1L therapy was 5.3 months with ABRAXANE + gemcitabine vs 3.7 months with gemcitabine alone
  • Patients had overall better performance status at baseline and at the end of 1L therapy compared with patients who did not get 2L therapy
  • 2L therapy consisted of 5–FU-based therapy for the majority of patients
Reasons for discontinuing 1L therapy ABRAXANE + gemcitabine vs gemcitabine:
  • Disease progression (59% vs 74%)
  • Adverse reactions (26% vs 14%)
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL